BioSyent Osake

BioSyent Osingo per osake

Osinko per osake yhtiöstä BioSyent (RX.V) 10.8.2026 päivämäärällä on 0,20 CAD. Edellisenä vuonna Osinko per osake oli 0,09 CAD — muutos 122,22 % (korkeampi).

Osingo per osake

0,20CAD

YoY

122,22%

Viimeksi päivitetty:

Osinko per osake yhtiöstä BioSyent on 2026 0,20 CAD. Osinko per osake yhtiöstä BioSyent oli 2025 0,09 CAD. Se laskee 122,22% korkeampi edelliseen vuoteen verrattuna.

BioSyent currently offers a dividend yield of about 1,33%. The payout ratio is around 17% of earnings. The dividend has grown at 71,0% per year over the past 3 years.

Access this data via the Eulerpool API

BioSyent Osakeanalyysi

Mitä BioSyent tekee? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset BioSyent osakkeesta

Yhtiön BioSyent Osinko per osake on 0,20 CAD vuonna 2026.

Osinko per osake yhtiöstä BioSyent muuttui arvosta 0,09 CAD arvoon 0,20 CAD, mikä edustaa 122,22 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää Osinko per osake BioSyent:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Osinko per osake on kokonasinsinko jaettuna ulkona olevilla osakkeilla. Se näyttää, kuinka paljon käteistä jokainen osake saa osinkona.

Osinko per osake:n CAD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata Osinko per osake:n BioSyent historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Osinko — BioSyent

Kaikki tunnusluvut — BioSyent